New therapeutic options for mesothelioma

Malignant pleural mesothelioma is an aggressive thoracic tumor that is often refractory to chemotherapy and radiotherapy, making long-term survival a difficult goal. Although multimodality therapies, including cytoreductive surgery, chemotherapy, and radiotherapy, have been tested, their survival be...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2005-08, Vol.7 (4), p.260-265, Article 260
Main Author: Goudar, Ranjit Kumar
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Chemotherapy
Combined Modality Therapy
Cytotoxic agents
Cytotoxicity
Humans
Lung cancer
Mesothelioma
Mesothelioma - drug therapy
Mesothelioma - radiotherapy
Mesothelioma - surgery
Neoadjuvant Therapy
Photochemotherapy
Pleural Neoplasms - drug therapy
Pleural Neoplasms - radiotherapy
Pleural Neoplasms - surgery
Radiation therapy
Survival
Thorax
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malignant pleural mesothelioma is an aggressive thoracic tumor that is often refractory to chemotherapy and radiotherapy, making long-term survival a difficult goal. Although multimodality therapies, including cytoreductive surgery, chemotherapy, and radiotherapy, have been tested, their survival benefit is unclear. Recently, novel cytotoxic agents such as pemetrexed have shown promise in the treatment of malignant pleural mesothelioma, and in early trials new small-molecule agents targeted to the specific biochemical properties of this tumor have shown promise.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-005-0048-3